Q-omics provides the consensus-scored ADAMTS17 profile across patient tissues and cancer cell-line models. ADAMTS17 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ADAMTS17 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, ADAMTS17 RNA expression shows 17,605 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRP, and GBM as cancer lineages where ADAMTS17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTS17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTS17 survival associations across molecular data types. ADAMTS17 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTS17 RNA expression–survival associations across cancer types. High ADAMTS17 expression shows unfavorable associations in MESO and UVM, but favorable associations in HNSC, LUSC, PAAD and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ADAMTS17 RNA expression.
This table summarizes ADAMTS17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ADAMTS17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTS17 shows lower tumor expression in KIRP, LUAD and CHOL and higher tumor expression in THCA, BRCA and LUSC. The KIRP box plot shows higher ADAMTS17 RNA expression in normal versus tumor tissue (log2 FC = −0.776, t-test p < 0.001).
This table shows molecular features associated with ADAMTS17 in patient tissues and cancer cell lines. In patient samples, ADAMTS17 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTS17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
